Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$860K
Filings
14
Firms Hired
1
Active Period
2020–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medicaid VBPs for Patients Act
2023 · fourth_quarter · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Transparency Policy Issues, Medicare Part D, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills); H.R. 2666 MVP Act, Medicaid Drug Rebate Program.
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 2666
Elijah E. Cummings Lower Drug Costs Now Act
2021 · first_quarter · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2021, Elijah Cummings Lower Drug Costs Now Act (H.R. 3)
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 3
Prescription Drug Pricing Reduction Act of 2020
2020 · fourth_quarter · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Client expense: $70,000 · Firm income: —
Matched citations: S.4199
Prescription Drug Pricing Reduction Act of 2020
2020 · third_quarter · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Client expense: $70,000 · Firm income: —
Matched citations: S.4199
Source: Senate LDA